Altered Body Composition and Cytokine Production in Patients with Elevated HOMA-IR after SARS-CoV-2 Infection: A 12-Month Longitudinal Study.

Altered Body Composition and Cytokine Production in Patients with Elevated HOMA-IR after SARS-CoV-2 Infection: A 12-Month Longitudinal Study.

Publication date: Jul 17, 2024

Altered body composition and cytokine production due to SARS-CoV-2 antigens may affect homeostasis model assessment for insulin resistance (HOMA-IR) after SARS-CoV-2 infection. To elucidate this phenomenon, we conducted a longitudinal study involving 47 COVID-19 patients, who were followed up for 12 months. During recruitment, body composition and glucose indices were measured, and heparin blood samples were collected for measuring cytokine production. HOMA-IR was considered an elevated or non-elevated group based on the ratio between HOMA-IR at 12 months and 1 month of convalescence. Those with elevated HOMA-IR had a significantly higher body mass index, body fat percentage, and visceral fat rating and had a lower lean mass and lean/fat mass ratio than their counterparts. During the convalescent period, the elevated HOMA-IR group had lower TNFα, IFNγ, IL-2, IL-10, and granzyme B expression levels but had higher TNFα/IL-10, IFNγ/IL-10, IL-2/IL-10, and granzyme B/IL-10 ratios than the other group. The reduced cytokine production and pro-/anti-inflammatory imbalance in patients with elevated HOMA-IR may suggest immune cell dysfunction toward SARS-CoV-2. Patients with elevated HOMA-IR after SARS-CoV-2 infection may experience an increase in BMI and body fat percentage, leading to increased immune dysfunction and chronic inflammatory condition. A nutritional approach and promotion of physical activity may help reduce HOMA-IR and ameliorate glucose indices in these patients.

Open Access PDF

Concepts Keywords
Biomedicines body composition
Homeostasis cytokines
Inflammatory diabetes
Insulin HOMA-IR
Month inflammation
post-COVID-19 condition

Semantics

Type Source Name
disease MESH SARS-CoV-2 Infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH insulin resistance
pathway KEGG Insulin resistance
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Heparin
disease IDO blood
disease MESH convalescence
drug DRUGBANK Interleukin-10
disease IDO cell
drug DRUGBANK Coenzyme M
disease MESH inflammation
disease MESH diabetes mellitus
disease IDO history
disease MESH infection
disease MESH reinfection
disease MESH sequelae
disease MESH autoimmune diseases
disease MESH long COVID
disease IDO immune response
disease MESH cytokine storm
disease MESH hyperglycemia
disease MESH obesity
disease VO time
disease VO vaccine
disease VO USA
disease MESH hyperinsulinemia
drug DRUGBANK Flunarizine
drug DRUGBANK Nitrogen
drug DRUGBANK Water
drug DRUGBANK Protein S human
disease IDO assay
disease VO manufacturer
disease VO protocol
disease VO ANOVA
disease VO vaccination
disease MESH Hypertension
disease MESH Kidney Failure
disease MESH Heart Failure
disease MESH Dyslipidemia
disease MESH Stroke
disease MESH COPD
disease MESH Asthma
pathway KEGG Asthma
disease VO frequency

Original Article

(Visited 2 times, 1 visits today)